Market capitalization | €26.32b |
Enterprise Value | €28.39b |
PER (TTM) P/E ratio | 76.55 |
EV/FCF (TTM) EV/FCF | 74.91 |
EV/Sales (TTM) EV/Sales | 5.41 |
P/S ratio (TTM) P/S ratio | 5.01 |
P/B ratio (TTM) P/B ratio | 2.93 |
Dividend yield | 0.98% |
Last dividend (FY24) | €1.36 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
19 Analysts have issued a UCB forecast:
19 Analysts have issued a UCB forecast:
Dec '23 |
+/-
%
|
||
Turnover | 5,252 5,252 |
5%
5%
|
|
Gross income | 3,342 3,342 |
9%
9%
|
|
EBITDA | 1,346 1,346 |
8%
8%
|
EBIT (operating result) EBIT | 655 655 |
1%
1%
|
Net profit | 343 343 |
18%
18%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Head office | Belgium |
CEO | Jean-Christophe Tellier |
Employees | 9,083 |
Founded | 1925 |
Website | www.ucb.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.